IDEAYA to Evaluate IDE161 in Combination with KEYTRUDA in Patients with Endometrial Cancer March 18, 2024
FDA Grants Priority Review to Supplemental BLA for KEYTRUDA Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma February 26, 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage ADC Pipeline February 26, 2024
Jemperli + Zejula combination significantly improved PFS in primary advanced or recurrent endometrial cancer in RUBY Part 2 Ph 3 trial January 4, 2024
FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer January 4, 2024
FAILED TRIAL: Ph 3 LEAP-001 Trial of KEYTRUDA + LENVIMA as 1L Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma did not meet primary dual endpoints December 11, 2023
New Preliminary OS data in Selinexor-Treated Patients with Advanced or Recurrent TP53 WT Endometrial Cancer from the SIENDO Study Announced December 4, 2023
Ph 3 RUBY trial of Jemperli + chemotherapy meets OS endpoint in patients with primary advanced or recurrent endometrial cancer November 7, 2023
Positive CHMP opinion recommending approval of Jemperli (dostarlimab) + chemo as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer October 25, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
Supplemental BLA accepted for priority review for Jemperli + chemo For The Treatment of dMMR/MSI-H Primary Advanced Or Recurrent Endometrial Cancer June 14, 2023
IMFINZI + LYNPARZA and IMFINZI alone both significantly improved PFS in advanced endometrial cancer when added to chemotherapy May 31, 2023
EMA Validates MAA for Jemperli (dostarlimab) + Chemo for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer May 10, 2023
Interim results from Part 1 of Ph 3 RUBY trial of Jemperli + chemo in adult patients with primary advanced or recurrent endometrial cancer announced April 6, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced/Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status April 6, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of MMR Status March 31, 2023
Clinical Responses from the Ph 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer highlighted February 22, 2023
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer February 22, 2023
NRG-GY018 Study Demonstrates Significantly Improved PFS Outcomes for Women with Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy February 8, 2023
